Investor Relations

Eton Pharmaceuticals, Inc. is a commercial company focused on developing, acquiring, and commercializing high-potential therapies for the treatment of patients with rare diseases. We have a diversified pipeline of product candidates across multiple therapeutic areas, and a team with significant expertise in bringing products from clinical trials to patients with exceptional speed.

Volume :

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases
June 15, 2021
Expands Eton’s Adrenal Insufficiency Orphan Drug Portfolio ZENEO® Hydrocortisone is Expected to be the First and Only Hydrocortisone Autoinjector for Patients Requiring Emergency Hydrocortisone Proprietary ZENEO® Needleless Device is Covered by 24 U.S.
June 15, 2021
DEER PARK, Ill. , June 15, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON) today announced that the U.S. Food and Drug Administration (FDA) has approved Rezipres ® (ephedrine hydrochloride injection) for the treatment of clinically important hypotension occurring in the setting of
May 28, 2021
DEER PARK, Ill. , May 28, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), today announced that the company has received a Complete Response Letter (CRL) from the U.S. Food & Drug Administration (FDA) in response to the submission of its New Drug Application (NDA) for dehydrated